Allosterism of acidic alcohol dehydrogenase (Class III ADH) of mouse liver and its role in alcohol metabolism.
スポンサーリンク
概要
- 論文の詳細を見る
Two major ADH isozymes of mouse liver, basic ADH (Class I) and acidic ADH (Class HI) were purified and the effects of various hydrophobic substances (t-butanol, butyramide, trifluoroethanol, trichloroacetic acid, stearic acid, oleamide, phenylalanine and norleucine) on their activities were investigated.<BR>All these hydrophobic substances activated acidic ADH with a range of from 15 to 560%, and reversely inactivated basic ADH activity with a range of from 10 to 100%, when 150mmol/<I>l</I> ethanol was used as a substrate. Among these substances, t-butanol, which was the most potent activator of acidic ADH, enhanced the activity by 560% and completely inactivated basic ADH at a concentration of 1.0mol/<I>l</I>.<BR>Kinetics studies demonstrated that the activation of acidic ADH by the hydrophobic substances was due to marked decreases of Km for ethanol in spite of decreases of Vmax, suggesting these substances were positive allosteric effectors for the isozyme. The inactivation of basic ADH by the hydrophobic substances was due to a decrease of Vmax without changing Km for ethanol. These results indicate that the activities of two ADH isozymes are regulated reversely by the hydrophobisity of the reaction environment which changes their kinetics constants.<BR>The ELISA method using the isozyme-specific antibody demonstrated that the content of acidic ADH in mouse liver was about 7 times larger than that of basic ADH (5.3.±0.86 vs 0.72.±0.06mg/g-liver).<BR>In the light of the hydrophobic regulation of ADH isozyme activities and their liver contents, the role of acidic ADH on alcohol metabolism may be more predominant than basic ADH in the liver under hydrophobic condition.
- 日本医科大学医学会の論文
日本医科大学医学会 | 論文
- わが国における腸チフスの疫学的考察--1973年〜1976年届出菌検出例を中心として
- 臨床および実験報告 二絨毛膜双胎妊娠における高年初産の検討
- 救急災害医学の確立と展望[含 略歴 研究業績] (定年退職教授記念講演会講演要旨)
- 臨床のために 関節リウマチの診断と治療
- TNFファミリーの制御による関節リウマチ治療の可能性 (特集 第15回公開「シンポジウム」(アレルギー・膠原病に対する新たな展開))